With thoughtful targeting at-scale, the company is successfully driving recruitment for pivotal trials for patients living with COPD
New York, NY (May 18, 2021) — For the 251 million people diagnosed with COPD worldwide, and the 3.71 million people who die from it every year, the need for new and better treatment options is clear. That’s why Antidote Technologies, a digital patient engagement company in the clinical trial recruitment space, is partnering with two large pharmaceutical companies to drive patient recruitment for their trials — and ultimately to contribute to COPD treatment progress.
Over the past three months, Antidote has efficiently connected more than 375,000 patients with information on these COPD trial opportunities, with more than 40,000 opting in and registering for Antidote's services to help them find a clinical trial. Antidote’s patient recruitment process begins with a thorough examination and understanding of the patients’ needs and motivations including: What are their pain points? What are they hoping to get out of treatment? Where is there an unmet need? With this information, Antidote develops customized digital marketing plans and taps into its extensive network of advocacy and lab partners to assist with reaching the right patients for each trial. Interested patients land on a digital pre-screener, which determines eligibility and provides details on how to continue the enrollment process. These COPD recruitment efforts continue, with the goal of more than 150 randomized patients across these projects.
“COPD is the third-leading cause of death in the United States,” said Laurent Schockmel, CEO of Antidote. “New and better treatments are needed now as are smarter and more efficient ways to find qualified volunteers who are interested in taking part in clinical trials. Patients just can't wait.”
If you are working on a COPD or respiratory trial and would like to discuss your clinical trial recruitment needs, please contact us:
About Antidote
Antidote is a digital health company on a mission to accelerate medical research. In a world where eighty percent of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me.
Media Contacts
Grace McElroy, Vice President of Marketing and Partnerships
grace@antidote.me
914-643-5260
Lisa Conroy, Head of Communications and Demand Generation
lisa@antidote.me
215-872-2917
